VEGFA and hepatocellular carcinoma: Similarly,in a study of 117 of patients with hepatocellular carcinoma treated withatezolizumab (an ICI) and bevacizumab (anti-vascular endothelial growth factor (VEGF) monoclonal antibody), there wasan increase in mean pulmonary artery diameter to aorta ratio on CT imaging aftertreatment (0.76 vs 0.79 mm, p< 0.001) [91].